Clinical Trials Browser

Phase 1/2 × Neoplasms × sotigalimab × Clear all

NCT03123783 2023-12-26

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Phase 1/2 Completed

140 enrolled 16 charts

DermatologicThoracic

Lung Neoplasms, Melanoma, Neoplasms